Hahn et al., 20169 |
Ipilimumab |
CTLA-4 |
Malignant melanoma |
AC inflammation, keratic precipitates |
Panuveitis, papillitis, intraretinal, subfoveal fluid |
Topical prednisolone acetate, brimonidine tartrate timolol maleate, oral prednisolone 20 mg/day |
Discontinued |
Aaberg et al., 201710 |
Pembrolizumab |
PD-1 |
Uveal melanoma |
AC inflammation, vitreous cells and haze |
Optic disc oedema, posterior uveitis, retinal vasculitis |
Intraocular dexamethasone implant |
No. |
Wang et al., 201911 |
Nivolumab |
PD-1 |
Renal carcinoma |
AC inflammation, keratoprecipitates, posterior synechiae, vitreous floaters |
Panuveitis, papillitis, serous retinal detachment |
Intravenous methylprednisolone 500 mg/day, followed by oral prednisolone 30 mg/day tapered over 2 months; recurrence of uveitis managed with periocular methylprednisolone, and intraocular dexamethasone implant |
Discontinued, resumed 6 weeks after discontinuation, recurrence of uveitis 2 weeks after resumption |
Reid et al., 201812 |
Pembrolizumab |
PD-1 |
Malignant melanoma |
AC vitreous inflammation, cells, choroidal thickening, posterior synechiae |
Panuveitis, optic disc oedema, hypotony |
Oral prednisolone 75 mg/day 7 days, tapered over 3 weeks |
Discontinued after 12 months commenced on nivolumab therapy |
Navarro- Perea et al., 201913 |
Pembrolizumab |
PD-1 |
Malignant melanoma |
AC inflammation, irido-crystalline synechiae |
Optic disc oedema |
Topical dexamethasone, cyclopentolate, tropicamide, phenylephrine, oral prednisolone 40 mg/day tapered over 2 months |
Discontinued, replaced by vemurafenib and cobimetinib |
Sun et al., 20205 |
Nivolumab |
PD-1 |
Malignant melanoma |
AC inflammation, vitreous cells, and haze |
Optic disc oedema, ocular hypertension |
Topical prednisolone acetate, oral prednisolone 60 mg/day |
n/a |
Sun 2020et 5 al., |
Pembrolizumab |
PD-1 |
Malignant melanoma |
AC inflammation |
Hypotony, Papillitis |
Topical difluprednate, subtenon triamcinolone acetonide |
n/a |
Sun et al., 20205 |
Ipilimumab |
PD-1 |
Malignant melanoma |
AC inflammation, vitreous cells |
Macular oedema, Papillitis |
Tiamcinolonetransseptal followed by retrobulbar) |
n/a |
Kim et al., 202014 |
Pembrolizumab |
PD-1 |
Renal carcinoma |
n/a |
Panuveitis, papillitis |
Topical steroid, posterior subtenon triamcinolone injection |
Discontinued |
Kim 2020et 14 al., |
Pembrolizumab |
PD-1 |
Uveal melanoma |
n/a |
Panuveitis, papillitis |
Systemic steroid |
Discontinued |
Kim 2020et 14 al. |
Pembrolizumab |
PD-1 |
Lung cancer |
n/a |
Panuveitis, uveal effusion papillitis, |
Systemic steroid |
Discontinued |
Kikuchi et al. 202015 |
Nivolumab |
PD-1 |
Hypopharyngeal cancer |
Granulomatous mutton-fat keratic precipitates, AC inflammation, posterior synechiae |
Panuveitis, papillitis, serous retinal detachment; Vogt- Koyanagi-Harada disease-like uveitis |
Sub-tenon triamcinolone acetonide, followed by methylprednisolone 1000 mg/day 3 days, followed by oral methylprednisolone 50 mg/day tapered by 5 mg every week |
Discontinued due to the patient’s deteriorating health |
Vrabic et al. |
durvalumab |
PDL-1 |
NSCLC |
AC inflammation, vitreous cells |
Intermediate uveitis, optic dics oedema |
Systemic steroid 500 mg/day 3 days, followed by oral methylprednisolone 48 mg/day tapered over 6 weeks |
Discontinued |